Fig. 5

The AQP1 expression correlated TMB, MSI, genomic changes and drug sensitivity in pan-cancer analysis. (A) Radar chart illustrated the correlation between TMB and AQP1 expression across various cancer types. Each spoke of the radar represented a different type of cancer. The distance from the center indicated the strength and direction of the correlation

outward represented a positive correlation, and inward indicated a negative correlation. Asterisks next to cancer types denoted statistical significance. AQP1 expression was negatively linked with TMB in UCEC, stomach adenocarcinoma (STAD), skin cutaneous melanoma (SKCM), pancreatic adenocarcinoma (PAAD), LUSC, HNSC, diffuse large B-cell lymphoma (DLBC), BLCA patients. (B) This radar chart illustrated the correlation between MSI and AQP1 expression across various cancer types. The blue line traces the correlation values for each cancer type, creating a profile of how AQP1 expression correlated with MSI across the pan-cancer analysis. AQP1 level was positively linked with MSI in LGG, KIRP, and THYM patients. It was negatively correlated in LUAD, LIHC, PAAD, THCA, STAD, PCPG, UCEC, SKCM, READ, HNSC, COAD, PRAD, CESC, LUSC, BLCA, and SARC patients. (C) The copy number alterations of AQP1. (D) The alteration frequency of AQP1 across various cancer types. (E) The mutation types of AQP1 in pan-cancer context. (F-G) The nine drugs whose sensitivity related to AQP1 expression predicted by CellMiner database. (H) The correlation between CTRP drugs and AQP1 mRNA expression. (I) The drugs whose sensitivity related to AQP1 mRNA expression predicted by CTRP. (J) The molecular docking analysis of AQP1 and PI-103. TMB, tumor mutation burden; MSI, microsatellite instability